• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Protagenic Therapeutics Inc (NQ: PTIX )

    0.7600 +0.0348 (+4.80%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,992
    Open 0.8000
    Bid (Size) 0.7582 (1)
    Ask (Size) 0.8400 (5)
    Prev. Close 0.7252
    Today's Range 0.7471 - 0.8258
    52wk Range 0.6797 - 2.220
    Shares Outstanding 4,435,132
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q1 2024
    Protagenic Therapeutics just reported results for the first quarter of 2024. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga

    Performance

    YTD
    -17.39%
    -17.39%
    1 Month
    -16.48%
    -16.48%
    3 Month
    -53.66%
    -53.66%
    6 Month
    -9.52%
    -9.52%
    1 Year
    -64.48%
    -64.48%

    More News

    Read More
    Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders
    Via ACCESSWIRE
    Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Protagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston Summit
    Via ACCESSWIRE
    Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results
    Via ACCESSWIRE
    Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023
    Via InvestorPlace
    Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
    Via ACCESSWIRE
    Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
    Via ACCESSWIRE
    Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
    Via ACCESSWIRE
    Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114
    Via ACCESSWIRE
    Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split
    Via ACCESSWIRE
    Earnings Scheduled For April 1, 2024
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Stocks That Hit 52-Week Lows On Thursday
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.